Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
O-7460
Cat. No.:
OB0425LY-070
Appearance:
Liquid
Purity:
≥95.0%
Identity:
Confirmed by NMR.
Size:
Add to basket
Product Overview
Description:
O-7460 is a potent and selective inhibitor of DAGLα.
Synonyms:
1572051-31-0; [1-[Fluoro(methyl)phosphoryl]oxy-3-propan-2-yloxypropan-2-yl] (Z)-octadec-9-enoate; 1-{[Fluoro(methyl)phosphoryl]oxy}-3-isopropoxy-2-propanyl (9Z)-9-octadecenoate
CAS No.:
1572051-31-0
Compound CID:
132285144
Formula:
C25H48FO5P
Formula Weight:
478.62
Specification
Target:
Cannabinoid receptor; DAGL
Pathway:
GPCR/G protein; Neuronal signaling; Metabolic enzyme/Protease
Storage:
Storage at -20°C.
Applications:
O-7460 can be used in the early stages of obesity drug development and also for high throughput screening.
